Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016:2016:4726078.
doi: 10.1155/2016/4726078. Epub 2016 Aug 25.

Endoscopic versus Percutaneous Biliary Drainage in Palliation of Advanced Malignant Hilar Obstruction: A Meta-Analysis and Systematic Review

Affiliations
Meta-Analysis

Endoscopic versus Percutaneous Biliary Drainage in Palliation of Advanced Malignant Hilar Obstruction: A Meta-Analysis and Systematic Review

Harsha Moole et al. Can J Gastroenterol Hepatol. 2016.

Abstract

Background. Palliation in advanced unresectable hilar malignancies can be achieved by endoscopic (EBD) or percutaneous transhepatic biliary drainage (PTBD). It is unclear if one approach is superior to the other in this group of patients. Aims. Compare clinical outcomes of EBD versus PTBD. Methods. (i) Study Selection Criterion. Studies using PTBD and EBD for palliation of advanced unresectable hilar malignancies. (ii) Data Collection and Extraction. Articles were searched in Medline, PubMed, and Ovid journals. (iii) Statistical Method. Fixed and random effects models were used to calculate the pooled proportions. Results. Initial search identified 786 reference articles, in which 62 articles were selected and reviewed. Data was extracted from nine studies (N = 546) that met the inclusion criterion. The pooled odds ratio for successful biliary drainage in PTBD versus EBD was 2.53 (95% CI = 1.57 to 4.08). Odds ratio for overall adverse effects in PTBD versus EBD groups was 0.81 (95% CI = 0.52 to 1.26). Odds ratio for 30-day mortality rate in PTBD group versus EBD group was 0.84 (95% CI = 0.37 to 1.91). Conclusions. In patients with advanced unresectable hilar malignancies, palliation with PTBD seems to be superior to EBD. PTBD is comparable to EBD in regard to overall adverse effects and 30-day mortality.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram: search results.
Figure 2
Figure 2
Forrest plot showing odds ratio of individual study proportion and pooled estimate comparing successful biliary drainage in PTBD versus EBD (fixed effects). ∗ refers to studies with single wing.
Figure 3
Figure 3
Funnel plot to evaluate publication bias (for successful biliary drainage in PTBD versus EBD).
Figure 4
Figure 4
Forrest plot showing odds ratio of individual study proportion and pooled estimate comparing successful biliary drainage in PTBD versus EBD, advanced HCCA subgroup (fixed effects).

References

    1. de Groen P. C., Gores G. J., LaRusso N. F., Gunderson L. L., Nagorney D. M. Biliary tract cancers. The New England Journal of Medicine. 1999;341(18):1368–1378. doi: 10.1056/nejm199910283411807. - DOI - PubMed
    1. Yusoff A. R., Siti Z. M., Muzammil A. R. M., Yoong B. K., Vijeyasingam R. Cholangiocarcinoma: a 10-year experience of a single tertiary centre in the Multi Ethnicity-Malaysia. Medical Journal of Malaysia. 2012;67(1):45–51. - PubMed
    1. Shaib Y., El-Serag H. B. The epidemiology of cholangiocarcinoma. Seminars in Liver Disease. 2004;24(2):115–125. doi: 10.1055/s-2004-828889. - DOI - PubMed
    1. Shin H.-R., Oh J.-K., Masuyer E., et al. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Science. 2010;101(3):579–585. doi: 10.1111/j.1349-7006.2009.01458.x. - DOI - PMC - PubMed
    1. Aljiffry M., Walsh M. J., Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990–2009. World Journal of Gastroenterology. 2009;15(34):4240–4262. doi: 10.3748/wjg.15.4240. - DOI - PMC - PubMed

LinkOut - more resources